- Home
- DXC vs ANAB Comparison
DXC vs ANAB Comparison
Compare DXC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXC | ANAB |
|---|---|---|
| Founded | 1959 | 2005 |
| Country | United States | United States |
| Employees | 115000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DXC | ANAB |
|---|---|---|
| Price | $15.31 | $48.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $12.50 | ★ $87.25 |
| AVG Volume (30 Days) | ★ 4.8M | 382.4K |
| Earning Date | 10-29-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $12,644,000,000.00 | $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $69.42 |
| P/E Ratio | $17.20 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $7.90 | $32.96 |
| 52 Week High | $16.38 | $73.30 |
Technical Indicators
Market Signals| Indicator | DXC | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 51.22 |
| Support Level | $11.07 | $44.25 |
| Resistance Level | $16.38 | $51.54 |
| Average True Range (ATR) | 0.72 | 1.77 |
| MACD | -0.13 | 0.24 |
| Stochastic Oscillator | 63.86 | 60.87 |
Price Performance
Historical ComparisonAbout DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).